Instem plc Perceptive Instruments Earn Out Payment (8002E)

TIDMINS

RNS Number : 8002E

Instem plc

13 February 2015

Instem plc

("Instem" or the "Company")

Perceptive Instruments Earn Out Payment

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that it has paid in full the performance based earn out of GBP300,000 in respect of the acquisition of Perceptive Instruments Limited ('Perceptive').

Earn Out Payment

As a result of Perceptive achieving all of the specified earn out targets for the period to 21 November 2014, the Vendors have been paid the maximum additional consideration of GBP300,000 in accordance with the Acquisition Agreement.

Background to the Acquisition

Instem acquired Perceptive in November 2013 for a maximum consideration of GBP1.3m, including the conditional earn out, marking the Company's entrance into the in vitro R&D marketplace.

Perceptive is located in Suffolk, UK, and develops, manufactures and supplies software and hardware products for in vitro study data collection and study management in the genetic toxicology, microbiology and immunology markets. Perceptive is the leading technology provider within its niche market and there are few competitors active in the space.

Phil Reason, CEO of Instem, said: "The acquisition of Perceptive has been a success, not only in terms of the financial contribution the acquisition has made to date, but also in terms of expanding the Company's offering into the in vitro data collection and study management in the genetic toxicology, microbiology and immunology markets. We are looking forward to another strong contribution from this area in 2015 and beyond."

For further information, please contact:

 
 Instem plc                         Tel: +44 (0) 1785 825 600 
 Phil Reason, CEO                              www.instem.com 
 Nigel Goldsmith, CFO 
 
 N+1 Singer (Nominated Adviser      Tel: +44 (0) 20 7496 3000 
  & Broker) 
 Richard Lindley 
 Nick Owen 
 
 Walbrook PR Ltd                 Tel: +44 (0) 20 7933 8780 or 
 Paul Cornelius                         instem@walbrookpr.com 
 Sam Allen 
 Nick Rome

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAKAAFSDSEFF

Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024